Organization
Wake Forest University School of Medicine
29 abstracts
Abstract
Phase 3 randomized placebo-controlled trial of donepezil for late cancer-related cognitive impairment in breast cancer survivors exposed to chemotherapy from the Wake Forest NCORP Research Base REMEMBER trial (WF97116).Org: Heartland NCORP, Minnesota Oncology Hematology PA - Coon Rapids, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Wake Forest University School of Medicine, Oncology Hematology Assoc of SW Indiana,
Abstract
Effectiveness of a cardiovascular health EHR application for cancer survivors in community oncology practice: Results from WF-1804CD.Org: University of Kansas School of Medicine, Wake Forest School of Medicine, Mercy Hospital Springfield, Washington University School of Medicine Saint Louis, Washington University in St. Louis School of Medicine,
Abstract
Frailty status determined by an electronic health record embedded frailty index and hospitalization risk among older adults following the initiation of cancer chemotherapy.Org: Wake Forest University School of Medicine, Levine Cancer Institute, Wake Forest Baptist Comprehensive Cancer Center,
Abstract
Therapeutic response and outcomes with less common breast cancer subtypes in the I-SPY trial 2011-2022.Org: Duke Cancer Institute, University of California, San Francisco, University of Utah, University of California, Davis Comprehensive Cancer Center, University of Chicago Medicine,
Abstract
EROS: Engendering reproductive health within oncologic survivorship—ECOG-ACRIN E1Q11 paradoxical provision of reproductive health.Org: Cook County Hospital, Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Lewis Cancer & Research Pavilion at St. Joseph's Candler/GA NCORP, SHCC MU-NCORP,
Abstract
If you build it, they will come: Success of the EROS (Engendering Reproductive Health Within Oncologic Survivorship)—ECOG-ACRIN E1Q11 in recruitment of minority patients.Org: Cook County Hospital, Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Lewis Cancer & Research Pavilion at St. Joseph's Candler/GA NCORP, SHCC MU-NCORP,
Abstract
Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis.Org: Memorial Sloan Kettering Cancer Center, Medical University of Silesia, Hematology Ward, S. Eugenio Hospital, The University of Texas MD Anderson Cancer Center,
Abstract
EROS: Engendering reproductive health within oncologic survivorship—ECOG-ACRIN E1Q11 assessing discrepancy in clinician-patient importance of sexuality over 2 years post-cancer diagnosis.Org: John H. Stroger, Jr. Hospital of Cook County, Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, University of Illinois Urbana-Champaign, Lewis Cancer & Research Pavilion at St. Joseph's Candler/GA NCORP,
Abstract
The CROWN study: Cardiac outcomes with near-complete estrogen deprivation.Org: Duke Cancer Institute, Wake Forest University School of Medicine, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Virginia Commonwealth University School of Medicine, VCU Health,
Abstract
COPD comorbidity and checkpoint inhibitor pneumonitis in a case-control study of patients with lung cancer.Org: Atrium Health Wake Forest Baptist Medical Center, Wake Forest Baptist Medical Center, Wake Forest University School of Medicine, Wake Forest School of Medicine, Winston-Salem, NC,
Abstract
Routine documentation of pre-treatment functional variables to predict survival in patients on immunotherapy.Org: Department of Hematology & Oncology, College of Medicine, University of Oklahoma Health Sciences Center, Wake Forest Baptist Medical Center, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Atrium Health Wake Forest Baptist Medical Center, Wake Forest University School of Medicine,
Abstract
Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.Org: Mayo Clinic, University of Alabama at Birmingham Department of Hematology, Birmingham, AL, University of Rochester Medical Center Department of Medical Oncology, Loyola University Medical Center, Vanderbilt University Medical Center,
Abstract
Smoking cessation support and knowledge among newly diagnosed individuals at community cancer centers (ECOG-ACRIN trial EAQ171CD).Org: Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Brown University–ECOG-ACRIN Biostatistics Center, Brown University - Lifespan Cancer Institute, University of Massachusetts Lowell,
Abstract
Impact of COVID-19 pandemic mitigation strategies on industry and NCI cancer treatment trials.Org: Fred Hutchinson Cancer Research Center, Seattle, WA, American Society of Clinical Oncology, Alexandria, VA, Friends of Cancer Research, Washington, DC,
Abstract
Lisavanbulin (BAL101553), a novel, oral microtubule destabilizer plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma: A phase 1 Adult Brain Tumor Consortium study (ABTC1601).Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Wake Forest University School of Medicine, University of Alabama-Birmingham, Henry Ford Hospital, University of Pittsburgh, Pittsburgh, PA,
Abstract
Patient reported quality of life (QOL) and survival outcomes: Analysis of ECOG-ACRIN E3805 chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PCa).Org: Beth Israel Deaconess Medical Center, Dana Farber Cancer Institute, Boston, MA, ECOG-ACRIN Biostatistics Center, University of Wisconsin Hospital and Clinics, Johns Hopkins Kimmel Cancer Center,
Abstract
Incidence and characterization of neurological adverse events among a retrospective cohort of patients receiving immune checkpoint inhibitors.Org: Wake Forest Baptist Medical Center, Wake Forest University School of Medicine,
Abstract
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis: Results from the ACE-536-MF-001 study.Org: Cleveland Clinic Taussig Cancer Instititute, Guy’s and St Thomas’ NHS Foundation Trust, Hopital Saint-Louis, Wake Forest University School of Medicine, AOU Careggi,
Abstract
Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.Org: University of California San Diego Medical Center, La Jolla, CA, Wake Forest University School of Medicine, University of California San Francisco, University of Rochester Medical Center Department of Medical Oncology, University of Alabama at Birmingham Department of Hematology, Birmingham, AL,
Abstract
Impact of transfusion burden on health-related quality of life (HRQOL) and functioning in patients (pts) with myelofibrosis (MF): Post hoc analysis of SIMPLIFY-1 (S1) and -2 (S2).Org: Wake Forest University School of Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna - Istituto di Ematologia “Seràgnoli”, Istituto di Ematologia Seràgnoli, University of Texas MD Anderson Cancer Center, Department of Leukemia, The University of Texas MD Anderson Cancer Center,
Abstract
Phase 3 randomized placebo-controlled trial of donepezil for cancer-related cognitive impairment among breast cancer survivors: Results on patient-reported cognitive function from the Wake Forest NCI Community Oncology Research Program (NCORP) Research Base REMEMBER trial (WF97116).Org: Wake Forest University School of Medicine, Wake Forest School of Medicine, Winston-Salem, NC, Physician's Clinic of Iowa, Cone Health Cancer Center, Wake Forest Baptist Medical Center,
Abstract
Sexual orientation and gender identity data collection among NCI community oncology research program (NCORP) practices: A 5-year landscape update.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Mayo Clinic, Wake Forest University School of Medicine, University of Wisconsin School of Medicine and Public Health, University of Rochester Medical Center,
Abstract
The CROWN study (CaRdiac Outcomes With Near complete estrogen deprivation): A multicenter, prospective cohort study of cardiovascular outcomes in premenopausal women with hormone receptor positive breast cancer treated with ovarian suppression and an aromatase inhibitor.Org: Wake Forest University School of Medicine, Wake Forest School of Medicine, Winston-Salem, NC, Duke Cancer Institute, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Virginia Commonwealth University School of Medicine,
Abstract
Cost and time estimates for integrating a cardiovascular health application for cancer survivors in the electronic health record: Case studies from the NCORP network.Org: Washington University in St. Louis School of Medicine, BJC HealthCare, Wake Forest University School of Medicine, Wake Forest University Department of General Internal Medicine,
Abstract
Feasibility of cryocompression for bortezomib-induced peripheral neuropathy (BIPN) among patients with multiple myeloma (MM).Org: Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, Wake Forest University School of Medicine,
Abstract
The 2022 NCI Community Oncology Research Program (NCORP) Landscape Committee Assessment: Methods and participating practice group characteristics.Org: Wake Forest University School of Medicine, University of Alabama at Birmingham Department of Hematology, Birmingham, AL, University of Wisconsin School of Medicine and Public Health, Tufts Medical Center/Tufts University, Spartanburg Regional Healthcare System,
Abstract
Telemedicine services in community oncology practices.Org: University of Rochester Medical Center, Rochester, NY, University of Rocheser Medical Center, Wake Forest University School of Medicine, Winston-Salem, NC,
Abstract
Implementation of an early-stage lung cancer survivorship clinic in a comprehensive cancer center.Org: Wake Forest School of Medicine, Winston-Salem, NC, Wake Forest University School of Medicine,
Abstract
Availability of palliative specialty care for adults in community oncology: Results from the 2022 NCORP Landscape Assessment.Org: Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, Wake Forest University School of Medicine, Spartanburg Regional Healthcare System, University of Rochester Medical Center,